TYK2 binds TYK2 inhibitors

Stable Identifier
R-HSA-9678737
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Non-receptor tyrosine-protein kinase TYK2 binds and is inhibited by several small molecule drugs (Clark et al. 2014, Gibbons et al. 2012). TYK2 is related to the Janus kinases (JAKs) family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. Drugs that inhibit these kinases are thus plausible candidates for treatment of severe host inflammatory reactions to viral infection (Richardson et al. 2020, Stebbing et al. 2020).

Literature References
PubMed ID Title Journal Year
32113509 COVID-19: combining antiviral and anti-inflammatory treatments

Stebbing, J, Phelan, A, Griffin, I, Tucker, C, Oechsle, O, Smith, D, Richardson, P

Lancet Infect Dis 2020
24417533 Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

Clark, JD, Flanagan, ME, Telliez, JB

J. Med. Chem. 2014
23061660 Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors

Hanan, EJ, van Abbema, A, Barrett, K, Blair, WS, Blaney, J, Chang, C, Eigenbrot, C, Flynn, S, Gibbons, P, Hurley, CA, Kenny, JR, Kulagowski, J, Lee, L, Magnuson, SR, Morris, C, Murray, J, Pastor, RM, Rawson, T, Siu, M, Ultsch, M, Zhou, A, Sampath, D, Lyssikatos, JP

J. Med. Chem. 2012
32032529 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Richardson, P, Griffin, I, Tucker, C, Smith, D, Oechsle, O, Phelan, A, Stebbing, J

Lancet 2020
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!